Log In
Print
BCIQ
Print
Print this Print this
 

Synriam, arterolane maleate/piperaquine phosphate

  Manage Alerts
Collapse Summary General Information
Company Ranbaxy Laboratories Ltd.
Description150 mg arterolane maleate and 750 mg piperaquine phospate
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationMalaria
Indication DetailsTreat malaria caused by Plasmodium Vivax; Treat malaria in adults
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today